Skip to main content
CRDF $0.87 +19.85%
CRDF logo
CRDF · Cardiff Oncology, Inc.
Track CRDF — free
$0.87 +0.14 (+19.85%) Q4 2024 earnings call transcript
Market Cap
$56.49M
Shares
77.80M
Volume · Nov 16 16.48M Avg daily vol (3M) 591.25K
All webcasts

Earnings call · FY2026 Q3

Cardiff Oncology, Inc. (CRDF) Q3 2026 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $171,000 +42.5% YoY
Diluted EPS -$0.12
Net income -$8.86M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start.
10-Q report · filed Nov 12, 2026
Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document